Rapport Therapeutics, Common Stock Shares Outstanding
| RAPP Stock | 24.00 1.16 5.08% |
Rapport Therapeutics, Common fundamentals help investors to digest information that contributes to Rapport Therapeutics,'s financial success or failures. It also enables traders to predict the movement of Rapport Stock. The fundamental analysis module provides a way to measure Rapport Therapeutics,'s intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Rapport Therapeutics, stock.
As of 12/02/2024, Common Stock Shares Outstanding is likely to drop to about 110.5 M. Rapport |
Rapport Therapeutics, Common Company Shares Outstanding Analysis
Rapport Therapeutics,'s Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Rapport Therapeutics, Shares Outstanding | 36.58 M |
Most of Rapport Therapeutics,'s fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Rapport Therapeutics, Common is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Rapport Shares Outstanding Driver Correlations
Understanding the fundamental principles of building solid financial models for Rapport Therapeutics, is extremely important. It helps to project a fair market value of Rapport Stock properly, considering its historical fundamentals such as Shares Outstanding. Since Rapport Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Rapport Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Rapport Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Rapport Shares Outstanding Historical Pattern
Today, most investors in Rapport Therapeutics, Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Rapport Therapeutics,'s growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's shares outstanding growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Rapport Therapeutics, shares outstanding as a starting point in their analysis.
Rapport Therapeutics, Shares Outstanding |
| Timeline |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Rapport Therapeutics, Common has 36.58 M of shares currently outstending. This is 79.74% lower than that of the Pharmaceuticals sector and 65.77% lower than that of the Health Care industry. The shares outstanding for all United States stocks is 93.6% higher than that of the company.
Rapport Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Rapport Therapeutics,'s direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Rapport Therapeutics, could also be used in its relative valuation, which is a method of valuing Rapport Therapeutics, by comparing valuation metrics of similar companies.Rapport Therapeutics, is currently under evaluation in shares outstanding category among its peers.
Rapport Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Rapport Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Rapport Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Rapport Fundamentals
| Current Valuation | 427.93 M | ||||
| Shares Outstanding | 36.58 M | ||||
| Shares Owned By Insiders | 6.53 % | ||||
| Shares Owned By Institutions | 93.47 % | ||||
| Number Of Shares Shorted | 1.74 M | ||||
| Price To Book | 2.26 X | ||||
| EBITDA | (34.66 M) | ||||
| Net Income | (34.79 M) | ||||
| Total Debt | 2.15 M | ||||
| Book Value Per Share | 9.21 X | ||||
| Cash Flow From Operations | (27.18 M) | ||||
| Short Ratio | 11.75 X | ||||
| Earnings Per Share | (1.72) X | ||||
| Target Price | 35.0 | ||||
| Market Capitalization | 762.25 M | ||||
| Total Asset | 155.42 M | ||||
| Retained Earnings | (45.44 M) | ||||
| Working Capital | 142.07 M | ||||
| Net Asset | 155.42 M |
About Rapport Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Rapport Therapeutics, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Rapport Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Rapport Therapeutics, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Rapport Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rapport Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rapport Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against Rapport Stock
| 0.48 | FATE | Fate Therapeutics | PairCorr |
| 0.38 | FENC | Fennec Pharmaceuticals | PairCorr |
| 0.37 | VRCA | Verrica Pharmaceuticals | PairCorr |
| 0.35 | A | Agilent Technologies | PairCorr |
| 0.34 | VRAX | Virax Biolabs Group | PairCorr |
The ability to find closely correlated positions to Rapport Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rapport Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rapport Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rapport Therapeutics, Common to buy it.
The correlation of Rapport Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rapport Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rapport Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rapport Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Rapport Stock Analysis
When running Rapport Therapeutics,'s price analysis, check to measure Rapport Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rapport Therapeutics, is operating at the current time. Most of Rapport Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Rapport Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rapport Therapeutics,'s price. Additionally, you may evaluate how the addition of Rapport Therapeutics, to your portfolios can decrease your overall portfolio volatility.